Global Medtech Companies Seeking Ways To Fortify Competitive Advantage In China
This article was originally published in PharmAsia News
Ranked only behind the U.S., China’s medtech market is set for a boom as more physicians are trained to perform common medical procedures that are still low-penetrating. Multinational manufacturers will have to fend off strong domestic firms.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.